Akebia Ther (AKBA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akebia Ther (AKBA) has a cash flow conversion efficiency ratio of 0.955x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($31.13 Million) by net assets ($32.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AKBA market cap for the company's overall valuation and market capitalisation.
Akebia Ther - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Akebia Ther's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Akebia Ther Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akebia Ther ranked by their cash flow conversion efficiency. Explore earnings quality score of Akebia Ther to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amazing Microelectronic
TWO:6411
|
0.027x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
|
G1 Secure Solutions Ltd
TA:GOSS
|
0.143x |
|
HengFeng Information Technology Co Ltd
SHE:300605
|
0.084x |
|
Asia Cement
KO:002030
|
0.032x |
|
Canada Nickel Company Inc
V:CNC
|
-0.014x |
|
Socovesa
SN:SOCOVESA
|
-0.130x |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
0.057x |
Annual Cash Flow Conversion Efficiency for Akebia Ther (2012–2025)
The table below shows the annual cash flow conversion efficiency of Akebia Ther from 2012 to 2025. View latest Akebia Ther stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $32.61 Million | $67.99 Million | 2.085x | +152.22% |
| 2024-12-31 | $-49.19 Million | $-40.66 Million | 0.827x | +8.12% |
| 2023-12-31 | $-30.58 Million | $-23.38 Million | 0.765x | +105.47% |
| 2022-12-31 | $5.23 Million | $-73.15 Million | -13.987x | -309.22% |
| 2021-12-31 | $74.01 Million | $-252.97 Million | -3.418x | -666.73% |
| 2020-12-31 | $247.62 Million | $-110.39 Million | -0.446x | +31.64% |
| 2019-12-31 | $394.76 Million | $-257.44 Million | -0.652x | -325.38% |
| 2018-12-31 | $635.93 Million | $-97.49 Million | -0.153x | +67.42% |
| 2017-12-31 | $119.33 Million | $-56.16 Million | -0.471x | -155.36% |
| 2016-12-31 | $68.12 Million | $57.91 Million | 0.850x | +312.48% |
| 2015-12-31 | $131.00 Million | $-52.41 Million | -0.400x | -51.50% |
| 2014-12-31 | $104.08 Million | $-27.48 Million | -0.264x | +28.33% |
| 2013-12-31 | $30.76 Million | $-11.33 Million | -0.368x | -113.69% |
| 2012-12-31 | $-2.68 Million | $-7.21 Million | 2.691x | -- |
About Akebia Ther
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and … Read more